Talc Cancer Risk: J&J Loses Again

A Pennsylvania jury has delivered a stunning $40 million verdict against Johnson & Johnson, ruling in favor of two women who developed ovarian cancer after years of using the company’s talc-based baby powder. This high-profile case exposes the potential dangers of a long-trusted American product and is the latest development in a wave of over 67,000 pending talc lawsuits that continue to pressure J&J amid repeated failures in its bankruptcy strategies to cap liabilities. Despite the company’s insistence that its talc is safe and asbestos-free, the jury’s decision, along with new NIH studies linking genital talc use to a 30% higher ovarian cancer risk, signals a growing legal and scientific consensus against the pharmaceutical giant.

Story Highlights

Pennsylvania jury awards $40 million in compensatory damages to two ovarian cancer victims for J&J’s failure to warn about talc risks.
Verdict adds to over 67,000 pending talc lawsuits, mostly ovarian cancer claims, pressuring J&J amid failed bankruptcy strategies.
J&J maintains talc is safe and asbestos-free but faces repeated jury losses despite scientific disputes.
New NIH studies link genital talc use to 30% higher ovarian cancer risk, bolstering plaintiffs after J&J’s third bankruptcy rejection in April 2025.
President Trump’s America First policies prioritize accountability, contrasting past regulatory leniency that let big pharma evade responsibility.

Pennsylvania Jury Delivers $40 Million Verdict

In September 2024, a Pennsylvania state-court jury ordered Johnson & Johnson to pay $40 million in damages to two women diagnosed with ovarian cancer. The plaintiffs used J&J’s talc-based powders, including Johnson’s Baby Powder, for years in the genital area. Jurors found J&J failed to warn about cancer risks from potential asbestos contamination or inherent carcinogenicity. This verdict covers medical costs, pain, and suffering. J&J plans to appeal, consistent with its strategy in similar cases.

Johnson & Johnson to pay $40M to 2 ovarian cancer patients after using brand’s talcum powders https://t.co/8LYgBg95AF pic.twitter.com/FypiUUm6hs

— New York Post (@nypost) December 13, 2025

Talc Litigation Explodes with Tens of Thousands of Claims

Johnson & Johnson faces about 67,670 pending federal talc lawsuits in MDL 2738 as of late 2025, predominantly ovarian cancer cases. Over 90,000 claims total allege long-term genital use caused cancer due to asbestos traces or particle migration to the ovaries. State courts in Pennsylvania, Missouri, and California host major trials. J&J disputes causation, citing its testing showing asbestos-free talc and inconsistent epidemiology. Yet juries increasingly side with plaintiffs, as seen in prior Missouri’s $2.12 billion award upheld after appeals.

Scientific Debate Fuels Jury Decisions

Concerns trace to the 1970s when talc particles appeared in ovarian tumors. Studies show long-term genital talc users face around 30-33% elevated ovarian cancer risk from inflammation. NIH-funded Journal of Clinical Oncology research in 2023-2024 confirmed significant links for frequent users. WHO assessments deem talc exposure likely carcinogenic.

J&J’s Bankruptcy Tactics Rejected Again

J&J spun off LTL Management for Chapter 11 filings to cap liabilities via the Texas two-step. Courts dismissed two attempts as bad faith, given J&J’s solvency. A third try with an $8-10 billion ovarian cancer settlement failed on April 1, 2025. This forces direct negotiations and trials. A July 2025 mediator now oversees talks after J&J’s $6.48 billion offer gained tentative plaintiff support but stalled. DOJ and HHS oppose, seeking over $1 billion in health cost recoupment. Recent mesothelioma verdicts, like $966 million in Los Angeles, heighten pressure.

Under President Trump’s leadership, Americans demand corporate accountability without government overreach. J&J pulled talc baby powder from U.S. markets, citing litigation, not safety, yet fights claims. Families trusted this product for infants and hygiene; verdicts highlight risks of unheeded warnings. Ongoing suits signal no quick end, with state verdicts like Pennsylvania’s setting benchmarks. Consumers must weigh science against defenses amid unresolved science.

Watch the report: Johnson & Johnson ordered to pay $40m to women who said talc to blame for cancer